NEW YORK (GenomeWeb) – As liquid biopsy products make further inroads in the clinic and in clinical research, rather than coalescing around a few dominant technologies or platforms, investigators and entrepreneurs are continuing to explore and advance a wide range of methods for examining genomic and other molecular biomarkers non-invasively.

This diversity was on full display at last week's annual meeting of the American Association for Cancer Research held in Washington, where studies stretched over five poster sessions and several symposia.